B. Treatment, Methylation Specific PCRs and RT-PCR DNAs were treated with bisulfite as indicated by the supplier, Methylation specific PCRs (M-PCR, U-PCR) and quantifying PCR (PCR-Q) were performed after a first amplification (PCR1)

P. , M. , U. , and P. Were, 20 and 19 cycles, respectively. The following primers were used: PCR-1 GTTTTGGGTTTTGGGAGTTGAGAG and ACCACCCACTTCTCCTATAAAA (874 bp; M-PCR GGGGTTATTATGGGTAGAGGATATC and ACATACTAAACGAATTCCGAACGACTC (109 bp); U-PCR GGGTTATTATGGGTAGAGGATATT and ACATACTAAACAAATTCCAAACAACTCTC (112 bp); and PCR Q TAAATAGTGGGTGAGTTATGAAGATGT and TACACCAAACCCTAACTAAAAAACC (285 bp) Extracted RNAs were reversed transcripted and amplified as previously described [12]. For TP73 RT-PCR assays, the following primers were used: TAp73 ex2-6 CACCACGTTTGAGCACCTCT and AGATTATTGCCTTCCACGCG (630 bp); TP73 ex7-10 GACGGAATTCACCACCATCCT and CCAGGCTCTCTTTCAGCTTC (389 bp); and ?Np73, pp.3-6

R. Fonseca, P. L. Bergsagel, J. Drach, J. Shaughnessy, N. Gutierrez et al., International Myeloma Working Group molecular classification of multiple myeloma: spotlight review, Leukemia, vol.91, issue.12, pp.2210-2221, 2009.
DOI : 10.1016/j.beha.2007.08.004

H. Avet-loiseau, M. Attal, L. Campion, D. Caillot, C. Hulin et al., Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival, Journal of Clinical Oncology, vol.30, issue.16, pp.1949-1952, 2012.
DOI : 10.1200/JCO.2011.36.5726

L. Lode, M. Eveillard, V. Trichet, T. Soussi, S. Wuilleme et al., Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma, Haematologica, vol.95, issue.11, pp.95-1973, 2010.
DOI : 10.3324/haematol.2010.023697

T. Meissner and S. Deshpande, Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma, Blood, vol.128, pp.1735-1744, 2016.

J. Martinez-lopez, M. I. Prieto-conde, and M. Garcia-alvarez, A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma, J. Mol. Diagn. 2017, vol.19, pp.99-106

G. Schon, Mutational landscape reflects the biological continuum of plasma cell dyscrasias, Blood Cancer J, vol.2017, issue.7

M. Jourdan, A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines, Haematologica, vol.96, pp.574-582, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00550232

C. Pellat-deceunynck, p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell, Blood Rev, vol.2017, issue.31, pp.251-259
URL : https://hal.archives-ouvertes.fr/inserm-01493742

V. J. Bykov, S. E. Eriksson, J. Bianchi, and K. G. Wiman, Targeting mutant p53 for efficient cancer therapy, Nature Reviews Cancer, vol.44, 2017.
DOI : 10.1093/nar/gkw010

S. Surget, G. Descamps, C. Brosseau, V. Normant, S. Maiga et al., RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53 abnormal myeloma cells independently of the p53 pathway, BMC Cancer, vol.19, issue.6, p.437, 2014.
DOI : 10.1038/cdd.2011.182

B. Tessoulin, G. Descamps, P. Moreau, S. Maiga, L. Lode et al., PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance, Blood, vol.124, issue.10, pp.1626-1636, 2014.
DOI : 10.1182/blood-2014-01-548800

B. Soldevilla, C. S. Millan, F. Bonilla, and G. Dominguez, The TP73 complex network: Ready for clinical translation in cancer? Genes Chromosomes Cancer, pp.989-1006, 2013.

J. Zawacka-pankau, A. Kostecka, A. Sznarkowska, and E. Hedstrom, Kawiak, A. p73 tumor suppressor protein: A close relative of p53 not only in structure but also in anti-cancer approach? Cell Cycle, pp.720-728, 2010.

S. Kawano, C. W. Miller, A. F. Gombart, C. R. Bartram, Y. Matsuo et al., Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation, Blood, vol.94, pp.1113-1120, 1999.

E. M. Alexandrova and U. M. Moll, Role of p53 family members p73 and p63 in human hematological malignancies, Leukemia & Lymphoma, vol.15, issue.11, pp.2116-2129, 2012.
DOI : 10.1016/j.leukres.2003.08.008

A. M. Maas, A. C. Bretz, E. Mack, and T. Stiewe, Targeting p73 in cancer, Cancer Letters, vol.332, issue.2, pp.229-236
DOI : 10.1016/j.canlet.2011.07.030

P. J. Teoh, C. Bi, C. Sintosebastian, L. S. Tay, R. Fonseca et al., PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation, Oncotarget, vol.7, issue.38, pp.61806-61819, 2016.
DOI : 10.18632/oncotarget.11241

S. Surget, D. Chiron, P. Gomez-bougie, G. Descamps, E. Menoret et al., Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells, Cancer Research, vol.72, issue.17, pp.4562-4573, 2012.
DOI : 10.1158/0008-5472.CAN-12-0487

D. Engelmann, C. Meier, V. Alla, and B. M. Putzer, A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression, Oncogene, vol.30, issue.33, pp.4287-4299, 2015.
DOI : 10.1038/onc.2010.635

S. Surget, E. Lemieux-blanchard, S. Maiga, G. Descamps, S. Le-gouill et al., Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other, Leukemia & Lymphoma, vol.296, issue.9, pp.2165-2173, 2014.
DOI : 10.1016/j.bbmt.2013.02.013

M. N. Saha, H. Jiang, Y. Yang, D. Reece, and H. Chang, PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa, Molecular Cancer Therapeutics, vol.12, issue.11, pp.2331-2341, 2013.
DOI : 10.1158/1535-7163.MCT-12-1166

U. M. Moll and N. Slade, p63 and p73: Roles in development and tumor formation, Mol. Cancer Res, vol.2, pp.371-386, 2004.

S. Polager and D. Ginsberg, p53 and E2f: partners in life and death, Nature Reviews Cancer, vol.416, issue.10, pp.738-748, 2009.
DOI : 10.1038/msb.2008.65

F. Conforti, A. E. Sayan, R. Sreekumar, and B. S. Sayan, Regulation of p73 activity by post-translational modifications, Cell Death & Disease, vol.1, issue.3, p.285
DOI : 10.1038/cddis.2010.85

P. Finzer, A. Krueger, M. Stohr, D. Brenner, U. Soto et al., HDAC inhibitors trigger apoptosis in HPV-positive cells by inducing the E2F???p73 pathway, Oncogene, vol.23, issue.28, pp.4807-4817, 2004.
DOI : 10.1074/jbc.M005600200